Omnic, 0.4 mg 100 pcs

Omnic selectively and competitively blocks postsynaptic α1A-adrenoreceptors located in the smooth muscles of the prostate, bladder neck and prostatic part of the urethra as well as α1D-adrenoreceptors mainly located in the bladder body.

This results in decreasing tone of the smooth muscles of the prostate, bladder neck and prostatic part of the urethra and improving detrusor function. Due to this the symptoms of obstruction and irritation associated with benign prostatic hyperplasia are decreased.

As a rule, therapeutic effect develops within 2 weeks after the beginning of drug intake, although some patients show reduction of symptoms after the first dose.

The ability of Omnik to affect α1A-adrenoreceptors is 20 times greater than its ability to interact with α1B-adrenoreceptors located in the vascular smooth muscle. Due to this high selectivity, the drug does not cause any clinically significant decrease in systemic BP both in patients with arterial hypertension and in patients with normal baseline BP.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Similarities